Kadcyla 100 mg (Trastuzumab Emtansine POWDER FOR SOLUTION) 100 MG

Kadcyla 100 mg is a powder for solution used in targeted cancer therapy. This medication combines trastuzumab emtansine to deliver treatment directly to cancer cells. Learn more about Kadcyla's uses and effects.

Strength

100 MG

Pack Size

15ML/20ML

Manufacturer / TM Owner

HOFFMANN-LA ROCHE LIMITED

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Kadcyla 100 mg is primarily used in the treatment of HER2-positive breast cancer. This medication is designed to target and destroy cancer cells while minimizing damage to healthy cells. Patients often wonder, 'What is Kadcyla used for?' It is typically prescribed for metastatic breast cancer that has progressed after other treatments.

Side Effects

Common effects of Kadcyla 100 mg may include fatigue, nausea, and muscle pain. Some patients experience more severe side effects, which should be discussed with a healthcare provider. The medication works by targeting specific proteins on cancer cells, which can lead to these effects.

Precautions & Warnings

Kadcyla 100 mg should be handled with care and administered by a healthcare professional. It is important to follow all safety guidelines when preparing and using this medication. Patients should be monitored for any adverse reactions during treatment.

Avoid Interactions

Kadcyla 100 mg may interact with other medications, including those that affect the immune system. It is important to inform your healthcare provider about all medications you are taking before starting Kadcyla. Alcohol and certain supplements may also interact with this medication.

References

Frequently Asked Questions

Kadcyla is used to treat HER2-positive breast cancer, particularly in cases where the cancer has spread or progressed after other treatments.

Kadcyla is administered intravenously by a healthcare professional. It is important to follow the prescribed dosage and administration schedule.

Common side effects of Kadcyla may include fatigue, nausea, and muscle pain. More severe side effects should be reported to a healthcare provider.

Kadcyla may interact with other medications, so it is important to discuss all current medications with your healthcare provider before starting treatment.

Kadcyla should be handled and administered by a healthcare professional. Patients should be monitored for any adverse reactions during treatment.

Published by GNH India Pharmaceuticals Limited

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.